

Applications of a Chemotype-Enrichment Approach to the ToxCast data landscape and beyond: *Inverting the SAR paradigm*



Coauthors:

Ryan Lougee
Christopher Grulke
Nancy Baker
Jun Wang
Antony Williams

Presenter: Ann Richard


National Center for Computational Toxicology
Office of Research & Development

richard.ann@epa.gov

Office of Research and Development
National Center for Computational Toxicology


This work was reviewed by EPA and approved for publication but does not necessarily reflect official Agency policy.

Global vs. Local SAR models




“Lensing”


For any given chemical-assay dataset, what is the optimal level of chemical and biological specificity to discover useful SAR associations?




Chemical/Substance representations for hazard & risk evaluation



Building a public chemotype “knowledge- base”




ToxCast HTS data



Chemotype-Activity Enrichments

- ✓ Create {CT-Activity} enrichment profiles for any “active” subspace of a test set
- ✓ Focus studies in local CT domains & compare enrichments across data domains



United States
Environmental Protection
Agency


ToxPrints: <http://www.toxprint.org>

[illegible][illegible][illegible]

Computing CT-Assay “Enrichments”

Set statistical thresholds & filters for significance to support data-mining objectives:

TP_ID	ToxPrint_CT_name ²	CT _{Tot}	T _{pos}	F _{pos}	F _{neg}	T _{neg}	Odd's Ratio	Fischer's pval
423	chain:alkaneBranch_t-butyl_C4	41	24	17	294	693	3.3	2.0E-04
479	chain:aromaticAlkane_Ph-C1-Ph	39	27	12	291	698	5.4	6.5E-07
303	bond:X[any_!C]_halide_inorganic	28	17	11	301	699	3.6	9.0E-04




Confusion matrix

TestSet = # Pos + # Neg = # chems tested


CT_{Tot} = total # chems in TestSet w/ CT (Pos or Neg)
 TP (T_{pos}) = # Pos in TestSet w/ CT
 FP (F_{pos}) = # Neg in TestSet w/ CT
 FN (F_{neg}) = # Pos in TestSet w/o CT
 TN (T_{neg}) = # Neg in TestSet w/o CT

- Odds Ratio ≥ 3 , *conveys simple fractional enrichment*
- Fischer's exact p value ≤ 0.05 , *takes into account size of dataset*
- T_{pos} (TP) ≥ 3 , *require at least 3 chemicals with CT in Positives*

United States
Environmental Protection
Agency



CTEW applied to all ToxCast assays in *invitroDB* (Dec-2017)



United States
Environmental Protection
Agency

“Global” QSAR models*
for 167 ToxCast Assays
Avg % Median BA = 0.67

Enriched CTs

1:

100

80

60

40

20

0

TOX21_GR_BLA_Agonist_ratio
TOX21_MMP_ratio_down
TOX21_p53_BLA_p3_viability
TOX21_p53_BLA_p3_chi2
TOX21_PPARC_BLA_p3_viability
TOX21_PPARC_BLA_Agonist_chi2
TOX21_PPARC_BLA_Agonist_ratio
TOX21_LAT_BLA_Agonist_chi2
ATG_AP_1_OIS_up
ATG_AP_1_OIS_down
ATG_GLOIS_up
ATG_GLOIS_down
BSK_3C_LPS_C16G_up
BSK_3C_LPS_C16G_down
BSK_CASMIC_Proliferation_down
BSK_4H_Paetelin_down
BSK_3C_KF-SCH1_L16_down
BSK_3C_KF-SCH1_L16_up
BSK_3C_FGF_F_down
BSK_3C_HLADR_down
BSK_HDFCGF_CollagenIII_down
BSK_HDFCGF_CollagenIII_up
BSK_3C_Zn2+_Zn2+_down
BSK_3C_Zn2+_Zn2+_up


Tested Chems (scaled)

United States
Environmental Protection
Agency

“Global” QSAR models*
for 167 ToxCast Assays
Avg % Median BA = 0.67

*Random Forest models based on ToxPrint CT descriptors, validated using independent Test Set & Y-randomization, with Training (100A,100I) & Test (25A,25I) Set minimums (J. Fitzpatrick)


“Global” QSAR models failed for 86% of ToxCast Assays



Significant CT-enrichments across ToxCast assay space considered “unmodelable” by traditional “global” QSAR methods


Enriched CT-count per assay trends (1032 assays)

*Does # enriched CTs depend on test set size? **YES!***



63 assays
enriched with
50-59 CTs


*Does # enriched CTs depend on %Actives? **Not so much.***



30-39 CTs enriched in
assays with avg Test
Set size 2264 chems

Assay-counts per enriched CT

*Enriched CT-counts
across 1032 assays*



Tuning biology to pick up chemical “signal”

CT Enrichments of Time-series* “Assays”

aenm_870unique	TP_Count	%actives	tested.chnm
APR_Hepat_Apoptosis_1hr_up	1	3.2	310
APR_Hepat_Apoptosis_24hr_up	15	14.8	310
APR_Hepat_Apoptosis_48hr_up	6	16.8	310
APR_Hepat_DNADamage_1hr_up	8	3.9	310
APR_Hepat_DNADamage_24hr_up	7	18.4	310
APR_Hepat_DNADamage_48hr_up	14	20.0	310

* 95 Assays out of 1032 total are within time-series groups





“Tuning” biology to
increase CT
enrichments →
increases
biological-
chemical “signal”

- How are {CT-assay} enrichments affected by activity threshold assumptions?
- How are {CT-assay} enrichments affected by cell toxicity (“burst”) filters? (R. Lougee)


Tuning chemistry to pick up biological “signal”

Assay Enrichments of chemistry-series groups



*“Tuning” chemistry
specificity to
increase
chemical-assay
“signal”*


What about the “Inactives”?




*More “CT-signal” in Actives, but
significant amount of signal in Inactives*

Inactive CT-enrichments

- Span ToxCast assay space
- More likely to occur in assays with fewer Active CT-enrichments
- May be due to several factors:
 - *True inactivity*
 - *Assay artifacts*
 - *QC failure*



Top 10 enriched CT-Inactives (skewed from actives)





*CT-Inactive >75 assays,
CT-active <10 assays*

- *True inactivity?*
- *Assay artifacts?*
- ***QC failure?***

Txp	CT Name	assay count (CT-Active enrichment)	assay count (CT-Inactive enrichment)
Txp-101	bond:CN_amine_pri-NH2_aromatic	3	84
Txp-145	bond:CX_halide_alkyl-Cl_ethyl	0	79
Txp-260	bond:P~S_generic	1	94
Txp-362	bond:metal_metalloid_oxy	2	96
Txp-372	bond:metal_metalloid_Si_organo	6	99
Txp-374	bond:metal_metalloid_Si_oxy	6	116
Txp-496	chain:oxy-alkaneLinear_ethyleneOxide_EO1(O)	5	91
Txp-497	chain:oxy-alkaneLinear_ethyleneOxide_EO2	6	127
Txp-607	ring:hetero_[4]_N_beta_lactam	1	118
Txp-663	ring:hetero_[6]_N_triazine_(1_3_5-)	2	234

ToxPrints enriched in Fails


Top 30 CTs enriched in QC “Fails” (vs. Scaled Pass)



Metals likely fail due to method-inadequacies, some very promiscuous

Top 30 CTs represented in 454/1130 (40%) QC “Fails”

CT Enrichments in Fluorescence Assays




CT's enriched (much more likely to be active) in "Fluorescence Assays" than in remaining assays


Multi-electrode array (MEA) neurotoxicity assay

Experimental Design


Determine Effects on Spontaneous Network Activity



Determine Effects on Cell Health



- Screened 1080 ToxCast Phase II chemicals
- Activity measured as Mean Firing Rate (MFR) above or below threshold




- 314 total “Actives” or Hits
- 758 “Inactives” or No-hits (8 cytotoxic)
- Total Tested = 1080 (30% hit rate)

MEA CT-Enrichment Analysis:

Overall coverage



■ % MEA Hits in Enriched Chemotype Group (Total MEA Hits=30%)



● Total Number of Tested MEA Chemicals in Chemotype Group




MEA CT-Enrichment Analysis:

Explore SAR within local CT domains



OR=5.4 (27/39 Hits)

OR=18.3 (8/9 hits)




MEA Hits

MEA Non-Hits


MEA CT-Enrichment Analysis: Use CTs to build biological linkages

MEA Hits


MEA Non-Hits



OR=11.3 (5/6 Hits)



OR=5.4 (27/39 Hits)



*ToxCast assays enriched with hits
in CT665 (OR > 4)*

NVS_GPCR_hOpiate_mu
NVS_GPCR_rOpiate_NonSelective
NVS_GPCR_rOpiate_NonSelectiveNa
NVS_IC_rCaBTZCHL
NVS_IC_rCaDHPRCh_L
NVS_IC_rNaCh_site2


4/5 MEA hits with CT665 also MEA hits in Ion Channel (IC) assays

16/27 MEA hits in CT479 also hits in NVS_IC assays

NIS Inhibition Assay

(with Jun Wang, Susan Laws et al.)

High-Throughput Screening and Chemotype-Enrichment Analysis of ToxCast Phase II Chemicals Evaluated for Human Sodium-Iodide Symporter (NIS) Inhibition



1028 ToxCast Phase II chemicals screened


→ 27% positive at 20% threshold in single screen ... **Hit1**

→ 6% positive in multiscreen, cell viability filtered results ... **Hit2**

NIS Activation Assay

Overall coverage

Top 9 CT's enriched in both Hit1 and Hit2 datasets




60% coverage of actives



Linking global inferences to local CT enrichment results

*CT Enriched
in 167 assays*


Number of ToxCast
assays with CT-
enriched in actives



Total No. Chemicals containing Enriched Chemotype




*Avg Hit rate for 12
cmpds containing
CT = 12%*



NIS Activation Assay

Inverse activity enrichments

Top 3 CT's enriched in both Hit1 and Hit2 "Inverse" datasets



NIS Activation Assay

Inverse activity enrichments


Top 3 CT's enriched in both Hit1 and Hit2 "Inverse" datasets

Txp-118 bond:COH_alcohol_aliphatic_generic


bond:COH_alcohol_pri-alkyl

bond:COH_alcohol_sec-alkyl

Total No. Chemicals containing
Inverse-Enriched Chemotype



Number of ToxCast
assays with CT-
enriched in actives




ToxPrints

- Txp-118 enriched in 42 ToxCast assays
- Avg assay hits per chemical containing Txp-118 is 8%

NIS Activation Assay

Exploring activity within CT domain




bond: CX_halide_a 142
lkenyl-X_generic



1

bond: CX_halide_aromatic 184
-X_ether_aromatic (Ph-O
-Ph)_generic




12

? (halogen) = F, Cl, I

- What distinguishes inactives in CT-subspace?
- What distinguishes the multiscreen Hit2 actives (HC2) from the single screen Hit1 (HC1) actives?

Random folds to select Hit2 set

→ 3 Random folds to select 63 HIT2 candidates from HIT2 set




Set	Total CT-Enrich	BA (full model)
HIT1	30	0.71
HIT2	23	0.75
Fold 1	15	0.71
Fold 2	19	0.71
Fold 3	16	0.71

HIT1: Single Screen

HIT2: Multiscreen + cell viability filters

Building a public chemotype “knowledge- base”



Acknowledgements:

- ✦ EPA NCCT Chemistry Team

Ryan Lougee (CTEW workflow coding)

Chris Grulke, Antony Williams (DSSTox, Chemotypes, Dashboard)

Jeremy Fitzpatrick (Global QSARs)

- ✦ ToxCast case studies

Tim Shafer, Jenna Strickland, Susan Laws, Jun Wang, Tammy Stoker

- ✦ ToxPrint Chemotypes

Chihae Yang, Jim Rathman & colleagues, Molecular Networks & Altamira

- ✦ NCCT & ToxCast Team



Thank you for your attention



Question

OR



Comment